Rotavirus virus-like particles administered mucosally induce protective immunity.
PDF (1.0M)
Journal: 1997/November - Journal of Virology
ISSN: 0022-538X
PUBMED: 9343229
Abstract:
We have evaluated the immunogenicity and protective efficacy of rotavirus subunit vaccines administered by mucosal routes. Virus-like particles (VLPs) produced by self-assembly of individual rotavirus structural proteins coexpressed by baculovirus recombinants in insect cells were the subunit vaccine tested. We first compared the immunogenicities and protective efficacies of VLPs containing VP2 and VP6 (2/6-VLPs) and G3 2/6/7-VLPs mixed with cholera toxin and administered by oral and intranasal routes in the adult mouse model of rotavirus infection. VLPs administered orally induced serum antibody and intestinal immunoglobulin A (IgA) and IgG. The highest oral dose (100 microg) of VLPs induced protection from rotavirus challenge >> or = 50% reduction in virus shedding) in 50% of the mice. VLPs administered intranasally induced higher serum and intestinal antibody responses than VLPs administered orally. All mice receiving VLPs intranasally were protected from challenge; no virus was shed after challenge. Since there was no difference in immunogenicity or protective efficacy between 2/6- and 2/6/7-VLPs, protection was achieved without inclusion of the neutralization antigens VP7 and VP4. We also tested the immunogenicities and protective efficacies of 2/6-VLPs administered intranasally without the addition of cholera toxin. 2/6-VLPs administered intranasally without cholera toxin induced lower serum and intestinal antibody titers than 2/6-VLPs administered with cholera toxin. The highest dose (100 microg) of 2/6-VLPs administered intranasally without cholera toxin resulted in a mean reduction in shedding of 38%. When cholera toxin was added, higher levels of protection were achieved with 10-fold less immunogen. VLPs administered mucosally offer a promising, safe, nonreplicating vaccine for rotavirus.
Open in
PUBMED | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(63)
References
(62)
Diseases
(1)
Chemicals
(7)
Organisms
(4)
Processes
(1)
Anatomy
(1)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
J Virol 71(11): 8707-8717
PMID: 9343229

Rotavirus virus-like particles administered mucosally induce protective immunity.

Abstract

We have evaluated the immunogenicity and protective efficacy of rotavirus subunit vaccines administered by mucosal routes. Virus-like particles (VLPs) produced by self-assembly of individual rotavirus structural proteins coexpressed by baculovirus recombinants in insect cells were the subunit vaccine tested. We first compared the immunogenicities and protective efficacies of VLPs containing VP2 and VP6 (2/6-VLPs) and G3 2/6/7-VLPs mixed with cholera toxin and administered by oral and intranasal routes in the adult mouse model of rotavirus infection. VLPs administered orally induced serum antibody and intestinal immunoglobulin A (IgA) and IgG. The highest oral dose (100 microg) of VLPs induced protection from rotavirus challenge (> or = 50% reduction in virus shedding) in 50% of the mice. VLPs administered intranasally induced higher serum and intestinal antibody responses than VLPs administered orally. All mice receiving VLPs intranasally were protected from challenge; no virus was shed after challenge. Since there was no difference in immunogenicity or protective efficacy between 2/6- and 2/6/7-VLPs, protection was achieved without inclusion of the neutralization antigens VP7 and VP4. We also tested the immunogenicities and protective efficacies of 2/6-VLPs administered intranasally without the addition of cholera toxin. 2/6-VLPs administered intranasally without cholera toxin induced lower serum and intestinal antibody titers than 2/6-VLPs administered with cholera toxin. The highest dose (100 microg) of 2/6-VLPs administered intranasally without cholera toxin resulted in a mean reduction in shedding of 38%. When cholera toxin was added, higher levels of protection were achieved with 10-fold less immunogen. VLPs administered mucosally offer a promising, safe, nonreplicating vaccine for rotavirus.

Full Text

The Full Text of this article is available as a PDF (1.0M).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Andrew ME, Boyle DB, Coupar BE, Reddy D, Bellamy AR, Both GW. Vaccinia-rotavirus VP7 recombinants protect mice against rotavirus-induced diarrhoea. Vaccine. 1992;10(3):185–191. [PubMed] [Google Scholar]
  • Bergmann KC, Waldman RH. Stimulation of secretory antibody following oral administration of antigen. Rev Infect Dis. 1988 Sep-Oct;10(5):939–950. [PubMed] [Google Scholar]
  • Bergquist C, Lagergård T, Lindblad M, Holmgren J. Local and systemic antibody responses to dextran-cholera toxin B subunit conjugates. Infect Immun. 1995 May;63(5):2021–2025.[PMC free article] [PubMed] [Google Scholar]
  • Both GW, Lockett LJ, Janardhana V, Edwards SJ, Bellamy AR, Graham FL, Prevec L, Andrew ME. Protective immunity to rotavirus-induced diarrhoea is passively transferred to newborn mice from naive dams vaccinated with a single dose of a recombinant adenovirus expressing rotavirus VP7sc. Virology. 1993 Apr;193(2):940–950. [PubMed] [Google Scholar]
  • Bridger JC, Oldham G. Avirulent rotavirus infections protect calves from disease with and without inducing high levels of neutralizing antibody. J Gen Virol. 1987 Sep;68(Pt 9):2311–2317. [PubMed] [Google Scholar]
  • Brown KA, Moser CA, Speaker TJ, Khoury CA, Kim JE, Offit PA. Enhancement by microencapsulation of rotavirus-specific intestinal immune responses in mice assessed by enzyme-linked immunospot assay and intestinal fragment culture. J Infect Dis. 1995 May;171(5):1334–1338. [PubMed] [Google Scholar]
  • Burns JW, Greenberg HB, Shaw RD, Estes MK. Functional and topographical analyses of epitopes on the hemagglutinin (VP4) of the simian rotavirus SA11. J Virol. 1988 Jun;62(6):2164–2172.[PMC free article] [PubMed] [Google Scholar]
  • Burns JW, Siadat-Pajouh M, Krishnaney AA, Greenberg HB. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science. 1996 Apr 5;272(5258):104–107. [PubMed] [Google Scholar]
  • Challacombe SJ. Cellular factors in the induction of mucosal immunity by oral immunization. Adv Exp Med Biol. 1987;216B:887–899. [PubMed] [Google Scholar]
  • Chiba S, Yokoyama T, Nakata S, Morita Y, Urasawa T, Taniguchi K, Urasawa S, Nakao T. Protective effect of naturally acquired homotypic and heterotypic rotavirus antibodies. Lancet. 1986 Aug 23;2(8504):417–421. [PubMed] [Google Scholar]
  • Ciarlet M, Hidalgo M, Gorziglia M, Liprandi F. Characterization of neutralization epitopes on the VP7 surface protein of serotype G11 porcine rotaviruses. J Gen Virol. 1994 Aug;75(Pt 8):1867–1873. [PubMed] [Google Scholar]
  • Clark HF, Borian FE, Bell LM, Modesto K, Gouvea V, Plotkin SA. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. J Infect Dis. 1988 Sep;158(3):570–587. [PubMed] [Google Scholar]
  • Coffin SE, Klinek M, Offit PA. Induction of virus-specific antibody production by lamina propria lymphocytes following intramuscular inoculation with rotavirus. J Infect Dis. 1995 Sep;172(3):874–878. [PubMed] [Google Scholar]
  • Conner ME, Crawford SE, Barone C, Estes MK. Rotavirus vaccine administered parenterally induces protective immunity. J Virol. 1993 Nov;67(11):6633–6641.[PMC free article] [PubMed] [Google Scholar]
  • Conner ME, Estes MK, Graham DY. Rabbit model of rotavirus infection. J Virol. 1988 May;62(5):1625–1633.[PMC free article] [PubMed] [Google Scholar]
  • Conner ME, Gilger MA, Estes MK, Graham DY. Serologic and mucosal immune response to rotavirus infection in the rabbit model. J Virol. 1991 May;65(5):2562–2571.[PMC free article] [PubMed] [Google Scholar]
  • Conner ME, Zarley CD, Hu B, Parsons S, Drabinski D, Greiner S, Smith R, Jiang B, Corsaro B, Barniak V, et al. Virus-like particles as a rotavirus subunit vaccine. J Infect Dis. 1996 Sep;174 (Suppl 1):S88–S92. [PubMed] [Google Scholar]
  • Crawford SE, Labbé M, Cohen J, Burroughs MH, Zhou YJ, Estes MK. Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells. J Virol. 1994 Sep;68(9):5945–5952.[PMC free article] [PubMed] [Google Scholar]
  • Dharakul T, Rott L, Greenberg HB. Recovery from chronic rotavirus infection in mice with severe combined immunodeficiency: virus clearance mediated by adoptive transfer of immune CD8+ T lymphocytes. J Virol. 1990 Sep;64(9):4375–4382.[PMC free article] [PubMed] [Google Scholar]
  • Ericson BL, Graham DY, Mason BB, Estes MK. Identification, synthesis, and modifications of simian rotavirus SA11 polypeptides in infected cells. J Virol. 1982 Jun;42(3):825–839.[PMC free article] [PubMed] [Google Scholar]
  • Feng N, Burns JW, Bracy L, Greenberg HB. Comparison of mucosal and systemic humoral immune responses and subsequent protection in mice orally inoculated with a homologous or a heterologous rotavirus. J Virol. 1994 Dec;68(12):7766–7773.[PMC free article] [PubMed] [Google Scholar]
  • Fiore L, Dunn SJ, Ridolfi B, Ruggeri FM, Mackow ER, Greenberg HB. Antigenicity, immunogenicity and passive protection induced by immunization of mice with baculovirus-expressed VP7 protein from rhesus rotavirus. J Gen Virol. 1995 Aug;76(Pt 8):1981–1988. [PubMed] [Google Scholar]
  • Flores J, Daoud G, Daoud N, Puig M, Martinez M, Perez-Schael I, Shaw R, Greenberg HB, Midthun K, Kapikian AZ. Reactogenicity and antigenicity of rhesus rotavirus vaccine (MMU-18006) in newborn infants in Venezuela. Pediatr Infect Dis J. 1988 Nov;7(11):776–780. [PubMed] [Google Scholar]
  • Franco MA, Greenberg HB. Role of B cells and cytotoxic T lymphocytes in clearance of and immunity to rotavirus infection in mice. J Virol. 1995 Dec;69(12):7800–7806.[PMC free article] [PubMed] [Google Scholar]
  • Franco MA, Tin C, Greenberg HB. CD8+ T cells can mediate almost complete short-term and partial long-term immunity to rotavirus in mice. J Virol. 1997 May;71(5):4165–4170.[PMC free article] [PubMed] [Google Scholar]
  • Gizurarson S, Jónsdóttir VM, Heron I. Intranasal administration of diphtheria toxoid. Selecting antibody isotypes using formulations having various lipophilic characteristics. Vaccine. 1995 May;13(7):617–621. [PubMed] [Google Scholar]
  • Haneberg B, Kendall D, Amerongen HM, Apter FM, Kraehenbuhl JP, Neutra MR. Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces. Infect Immun. 1994 Jan;62(1):15–23.[PMC free article] [PubMed] [Google Scholar]
  • Heinz FX, Roggendorf M, Hofmann H, Kunz C, Deinhardt F. Comparison of two different enzyme immunoassays for detection of immunoglobulin M antibodies against tick-borne encephalitis virus in serum and cerebrospinal fluid. J Clin Microbiol. 1981 Aug;14(2):141–146.[PMC free article] [PubMed] [Google Scholar]
  • Herbrink P, van Loon AM, Rotmans JP, van Knapen F, van Dijk WC. Interlaboratory evaluation of indirect enzyme-linked immunosorbent assay, antibody capture enzyme-linked immunosorbent assay, and immunoblotting for detection of immunoglobulin M antibodies to Toxoplasma gondii. J Clin Microbiol. 1987 Jan;25(1):100–105.[PMC free article] [PubMed] [Google Scholar]
  • Hirabayashi Y, Kurata H, Funato H, Nagamine T, Aizawa C, Tamura S, Shimada K, Kurata T. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination. Vaccine. 1990 Jun;8(3):243–248. [PubMed] [Google Scholar]
  • Hoshino Y, Saif LJ, Sereno MM, Chanock RM, Kapikian AZ. Infection immunity of piglets to either VP3 or VP7 outer capsid protein confers resistance to challenge with a virulent rotavirus bearing the corresponding antigen. J Virol. 1988 Mar;62(3):744–748.[PMC free article] [PubMed] [Google Scholar]
  • Khoury CA, Moser CA, Speaker TJ, Offit PA. Oral inoculation of mice with low doses of microencapsulated, noninfectious rotavirus induces virus-specific antibodies in gut-associated lymphoid tissue. J Infect Dis. 1995 Sep;172(3):870–874. [PubMed] [Google Scholar]
  • LeBaron CW, Lew J, Glass RI, Weber JM, Ruiz-Palacios GM. Annual rotavirus epidemic patterns in North America. Results of a 5-year retrospective survey of 88 centers in Canada, Mexico, and the United States. Rotavirus Study Group. JAMA. 1990 Aug 22;264(8):983–988. [PubMed] [Google Scholar]
  • Lycke N, Holmgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology. 1986 Oct;59(2):301–308.[PMC free article] [PubMed] [Google Scholar]
  • Mackow ER, Vo PT, Broome R, Bass D, Greenberg HB. Immunization with baculovirus-expressed VP4 protein passively protects against simian and murine rotavirus challenge. J Virol. 1990 Apr;64(4):1698–1703.[PMC free article] [PubMed] [Google Scholar]
  • Matsui SM, Offit PA, Vo PT, Mackow ER, Benfield DA, Shaw RD, Padilla-Noriega L, Greenberg HB. Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to the heterotypic neutralization domain of VP7 and the VP8 fragment of VP4. J Clin Microbiol. 1989 Apr;27(4):780–782.[PMC free article] [PubMed] [Google Scholar]
  • Mattingly JA, Waksman BH. Immunologic suppression after oral administration of antigen. II. Antigen-specific helper and suppressor factors produced by spleen cells of rats fed sheep erythrocytes. J Immunol. 1980 Sep;125(3):1044–1047. [PubMed] [Google Scholar]
  • McDermott MR, Bienenstock J. Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues. J Immunol. 1979 May;122(5):1892–1898. [PubMed] [Google Scholar]
  • McNeal MM, Barone KS, Rae MN, Ward RL. Effector functions of antibody and CD8+ cells in resolution of rotavirus infection and protection against reinfection in mice. Virology. 1995 Dec 20;214(2):387–397. [PubMed] [Google Scholar]
  • Offit PA, Clark HF. Protection against rotavirus-induced gastroenteritis in a murine model by passively acquired gastrointestinal but not circulating antibodies. J Virol. 1985 Apr;54(1):58–64.[PMC free article] [PubMed] [Google Scholar]
  • Offit PA, Dudzik KI. Noninfectious rotavirus (strain RRV) induces an immune response in mice which protects against rotavirus challenge. J Clin Microbiol. 1989 May;27(5):885–888.[PMC free article] [PubMed] [Google Scholar]
  • Offit PA, Dudzik KI. Rotavirus-specific cytotoxic T lymphocytes passively protect against gastroenteritis in suckling mice. J Virol. 1990 Dec;64(12):6325–6328.[PMC free article] [PubMed] [Google Scholar]
  • Offit PA, Khoury CA, Moser CA, Clark HF, Kim JE, Speaker TJ. Enhancement of rotavirus immunogenicity by microencapsulation. Virology. 1994 Aug 15;203(1):134–143. [PubMed] [Google Scholar]
  • Offit PA, Shaw RD, Greenberg HB. Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to surface proteins vp3 and vp7. J Virol. 1986 May;58(2):700–703.[PMC free article] [PubMed] [Google Scholar]
  • O'Ryan ML, Matson DO, Estes MK, Pickering LK. Anti-rotavirus G type-specific and isotype-specific antibodies in children with natural rotavirus infections. J Infect Dis. 1994 Mar;169(3):504–511. [PubMed] [Google Scholar]
  • Perez-Schael I, Garcia D, Gonzalez M, Gonzalez R, Daoud N, Perez M, Cunto W, Kapikian AZ, Flores J. Prospective study of diarrheal diseases in Venezuelan children to evaluate the efficacy of rhesus rotavirus vaccine. J Med Virol. 1990 Mar;30(3):219–229. [PubMed] [Google Scholar]
  • Quiding-Järbrink M, Granström G, Nordström I, Holmgren J, Czerkinsky C. Induction of compartmentalized B-cell responses in human tonsils. Infect Immun. 1995 Mar;63(3):853–857.[PMC free article] [PubMed] [Google Scholar]
  • Rudzik R, Clancy RL, Perey DY, Day RP, Bienenstock J. Repopulation with IgA-containing cells of bronchial and intestinal lamina propria after transfer of homologous Peyer's patch and bronchial lymphocytes. J Immunol. 1975 May;114(5):1599–1604. [PubMed] [Google Scholar]
  • Sheridan JF, Smith CC, Manak MM, Aurelian L. Prevention of rotavirus-induced diarrhea in neonatal mice born to dams immunized with empty capsids of simian rotavirus SA-11. J Infect Dis. 1984 Mar;149(3):434–438. [PubMed] [Google Scholar]
  • Smith JC, Haddix AC, Teutsch SM, Glass RI. Cost-effectiveness analysis of a rotavirus immunization program for the United States. Pediatrics. 1995 Oct;96(4 Pt 1):609–615. [PubMed] [Google Scholar]
  • Sosroseno W. A review of the mechanisms of oral tolerance and immunotherapy. J R Soc Med. 1995 Jan;88(1):14–17.[PMC free article] [PubMed] [Google Scholar]
  • Staats HF, Nichols WG, Palker TJ. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). J Immunol. 1996 Jul 1;157(1):462–472. [PubMed] [Google Scholar]
  • Tamura SI, Samegai Y, Kurata H, Kikuta K, Nagamine T, Aizawa C, Kurata T. Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine. Vaccine. 1989 Jun;7(3):257–262. [PubMed] [Google Scholar]
  • Tamura S, Samegai Y, Kurata H, Nagamine T, Aizawa C, Kurata T. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. Vaccine. 1988 Oct;6(5):409–413. [PubMed] [Google Scholar]
  • VanCott JL, Brim TA, Lunney JK, Saif LJ. Contribution of antibody-secreting cells induced in mucosal lymphoid tissues of pigs inoculated with respiratory or enteric strains of coronavirus to immunity against enteric coronavirus challenge. J Immunol. 1994 Apr 15;152(8):3980–3990. [PubMed] [Google Scholar]
  • Ward RL, Bernstein DI, Shukla R, Young EC, Sherwood JR, McNeal MM, Walker MC, Schiff GM. Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J Infect Dis. 1989 Jan;159(1):79–88. [PubMed] [Google Scholar]
  • Ward RL, McNeal MM, Sheridan JF. Development of an adult mouse model for studies on protection against rotavirus. J Virol. 1990 Oct;64(10):5070–5075.[PMC free article] [PubMed] [Google Scholar]
  • Ward RL, McNeal MM, Sheridan JF. Evidence that active protection following oral immunization of mice with live rotavirus is not dependent on neutralizing antibody. Virology. 1992 May;188(1):57–66. [PubMed] [Google Scholar]
  • Weisz-Carrington P, Roux ME, McWilliams M, PHILLIPS-Quagliata JM, Lamm ME. Organ and isotype distribution of plasma cells producing specific antibody after oral immunization: evidence for a generalized secretory immune system. J Immunol. 1979 Oct;123(4):1705–1708. [PubMed] [Google Scholar]
  • Woode GN, Zheng SL, Rosen BI, Knight N, Gourley NE, Ramig RF. Protection between different serotypes of bovine rotavirus in gnotobiotic calves: specificity of serum antibody and coproantibody responses. J Clin Microbiol. 1987 Jun;25(6):1052–1058.[PMC free article] [PubMed] [Google Scholar]
  • Wu HY, Russell MW. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit. Infect Immun. 1993 Jan;61(1):314–322.[PMC free article] [PubMed] [Google Scholar]
  • Yuan L, Ward LA, Rosen BI, To TL, Saif LJ. Systematic and intestinal antibody-secreting cell responses and correlates of protective immunity to human rotavirus in a gnotobiotic pig model of disease. J Virol. 1996 May;70(5):3075–3083.[PMC free article] [PubMed] [Google Scholar]
Division of Molecular Virology, Baylor College of Medicine, Houston, Texas 77030, USA.
Division of Molecular Virology, Baylor College of Medicine, Houston, Texas 77030, USA.
Copyright notice

Abstract

We have evaluated the immunogenicity and protective efficacy of rotavirus subunit vaccines administered by mucosal routes. Virus-like particles (VLPs) produced by self-assembly of individual rotavirus structural proteins coexpressed by baculovirus recombinants in insect cells were the subunit vaccine tested. We first compared the immunogenicities and protective efficacies of VLPs containing VP2 and VP6 (2/6-VLPs) and G3 2/6/7-VLPs mixed with cholera toxin and administered by oral and intranasal routes in the adult mouse model of rotavirus infection. VLPs administered orally induced serum antibody and intestinal immunoglobulin A (IgA) and IgG. The highest oral dose (100 microg) of VLPs induced protection from rotavirus challenge (> or = 50% reduction in virus shedding) in 50% of the mice. VLPs administered intranasally induced higher serum and intestinal antibody responses than VLPs administered orally. All mice receiving VLPs intranasally were protected from challenge; no virus was shed after challenge. Since there was no difference in immunogenicity or protective efficacy between 2/6- and 2/6/7-VLPs, protection was achieved without inclusion of the neutralization antigens VP7 and VP4. We also tested the immunogenicities and protective efficacies of 2/6-VLPs administered intranasally without the addition of cholera toxin. 2/6-VLPs administered intranasally without cholera toxin induced lower serum and intestinal antibody titers than 2/6-VLPs administered with cholera toxin. The highest dose (100 microg) of 2/6-VLPs administered intranasally without cholera toxin resulted in a mean reduction in shedding of 38%. When cholera toxin was added, higher levels of protection were achieved with 10-fold less immunogen. VLPs administered mucosally offer a promising, safe, nonreplicating vaccine for rotavirus.

Abstract
Full Text
Selected References
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.